Seizure Advisory System Feasibility Study

This study has been terminated.
(Sponsor restructuring.)
Sponsor:
Information provided by (Responsible Party):
NeuroVista Corporation
ClinicalTrials.gov Identifier:
NCT01043406
First received: January 4, 2010
Last updated: October 22, 2012
Last verified: October 2012

January 4, 2010
October 22, 2012
March 2010
August 2012   (final data collection date for primary outcome measure)
The primary evaluation of safety will be an assessment of adverse events . [ Time Frame: Adverse events through the primary safety endpoint four months post-implant. ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01043406 on ClinicalTrials.gov Archive Site
  • Seizure advisory performance will be assessed for the study population. [ Time Frame: At the primary advisory performance endpoint at the conclusion of the Data Collection Phase (approximately 3 months post-implant) . ] [ Designated as safety issue: No ]
  • Clinical effectiveness will be evaluated. [ Time Frame: At the primary clinical effectiveness endpoint 4 months following the commencement of the Advisory Phase (approximately 7 months post-implant) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Seizure Advisory System Feasibility Study
Safety and Effectiveness of a Seizure Advisory System in Epilepsy: A Feasibility Study (Victoria)

The purpose of this prospective, single-arm, unblinded, multicenter clinical study is to evaluate the safety and effectiveness of the NeuroVista Seizure Advisory System (SAS) in patients with medically refractory epilepsy. A total of 15 subjects will be implanted at up to three study sites.

This research project aims to evaluate the effectiveness of the SAS based on how well it provides subjects with signals (or "advisories") that they can see and hear to predict their "likelihood" of having a seizure. It does this by monitoring signals in the brain. A secondary purpose of the study is to learn whether the advisories improve subject quality of life or that of their caregiver.

The SAS is made up of three main components that work together to monitor the subject's brain signals and then relay their information to the subject: the leads, the implantable telemetry unit (ITU), and the personal advisory device (PAD). The leads will be placed on different areas of the subject's brain to record electrical signals. The leads are tunneled down the neck to an ITU that is implanted in the chest, similar to a pacemaker. The ITU wirelessly transmits information to the PAD, which is carried like a pager. It records and processes brain signals and may be able to advise subjects when a seizure is likely or unlikely to occur.

Following implantation with the SAS, subjects will return for five study visits for neurological examinations and quality of life assessments. Throughout the study, subjects must maintain their SAS; which includes daily recharging and data card replacement.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Epilepsy
Device: Seizure Advisory System
Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
Experimental: Single Arm, Device Implant
Intervention: Device: Seizure Advisory System

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
15
October 2012
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subject has disabling partial seizures and/or secondarily generalized partial seizures. Disabling refers to seizures that are severe enough to cause injuries or to significantly impair areas of function such as employment, psychological or social wellbeing, or mobility.
  2. Subject has failed treatment with a minimum of two AED's used in typical therapeutic dosages.
  3. For three months prior to enrollment, subject's anti-epileptic medication dosages have been stable and subject has had at least two disabling seizures per month, on average, with a seizure-free interval not to exceed 45 days. Seizures must be separated by a minimum of eight hours not to be considered part of a cluster. A cluster, for the purpose of this criterion, shall be considered a single seizure.

Exclusion Criteria:

  1. For three months prior to enrollment, subject's anti-epileptic medication dosages have not been stable, or subject has had more than 12 disabling seizures per month, on average, or there was a seizure-free interval longer than 45 days. Clinical seizures must be separated by a minimum of eight hours to not be considered part of a cluster. A cluster, for the purpose of this criterion, shall be considered a single seizure.
  2. Subject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the SAS or with which the SAS interferes. This includes, but is not limited to, direct brain neurostimulators, spinal cord stimulators, vagus nerve stimulators (VNS), and cochlear implants. Patients with a vagus nerve stimulator implanted but turned off through the duration of the study may be enrolled, provided their clinical status has been stable for at least one month with VNS turned off.
  3. Subject has been diagnosed with primary generalized seizures.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Australia
 
NCT01043406
NVC1001
No
NeuroVista Corporation
NeuroVista Corporation
Not Provided
Study Director: Warren D Sheffield, VMD, PhD NeuroVista Corporation
NeuroVista Corporation
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP